

DEVELOPMENT & EVALUATION OF INTRA-NASAL LIPID NANOCARRIERS FOR LUNG CANCER



Thesis submitted in partial fulfilment for
the Award of Degree

Doctor of Philosophy

By

Mohini Mishra

DEPARTMENT OF PHARMACEUTICAL ENGINEERING AND TECHNOLOGY
INDIAN INSTITUTE OF TECHNOLOGY
(BANARAS HINDU UNIVERSITY)
VARANASI-221005
INDIA

Roll No. 19161005

Year 2025

PREFACE

Lung cancer represents the most common root cause of deaths related to cancer around the world. According to Cancer Statistics, 2024, published in CA: A Cancer Journal for Clinicians, 2,001,140 new cases of cancer have been reported with 611,720 deaths due to cancer in the United States and nearly 1680 deaths per day. The greatest number of deaths are reported to be due to lung cancer which is reported to be more than breast cancer, prostate cancer, pancreatic cancer, and colorectal cancer. Chemotherapy has emerged as a boon for the management and treatment of cancer in conjunction with radiation therapy, surgery, and targeted therapy. But conventional synthetic drugs used as chemotherapeutic agents for the treatment of lung cancer have been reported to incite associated nonspecific and systemic cytotoxicity and this leads to a hunt for better biologically compatible compounds of natural origin-based chemotherapy that could be explored as alternative therapy for lung cancer. Solid lipid nanoparticles are a colloidal carrier system encompassing solid lipid, water, and surfactant. The obvious merits of SLNs over nanoemulsions and polymer-based nanoparticles are enhanced stability of the drug, accentuated drug entrapment efficiency and biocompatibility as these are mostly formulated from biodegradable excipients and generally regarded as safe (GRAS) certified excipients. Apart from these merits SLNs also command the encapsulated drug release and averts the premature degradation of the drug in the system[1][1](Radhakrishnan et al., 2016)(Radhakrishnan et al., 2016)(Radhakrishnan et al., 2016). Conventional treatment approaches of lung cancer offer not so satisfactory results, and a compromised life associated with potential side effects of chemotherapy, radiation therapy, and surgical resection. In the absence of targeted therapies, systemic administration of chemotherapy exposes normal cells to these potent chemotherapeutic drugs resulting in the inhibition of their growth making patient weak and could eventually leads to death. Therefore, intranasal administration of chemotherapeutic drugs could pave a way for the

efficient delivery of these potent drugs directly to lungs and avoiding first pass metabolism and other potential side effects associated with systemic route of drug administration.

The aim of our study was to design, optimize, develop, characterize, and evaluate the gemcitabine and epigallocatechin-3-gallate loaded solid lipid nanoparticles (GEM-EGCG SLNs) against lung cancer via intranasal route. The SLNs were prepared by double emulsification solvent evaporation method and characterized for micromeritics and physiochemical characterization with entrapment efficiency and drug release kinetics. Further, the GEM-EGCG SLNs were also evaluated for *in vitro* cell line studies against A549 lung cancer cell lines. A proportional decrease in the percent cell viability of A549 cells has been noticed with an increase in the concentration of GEM-EGCG SLNs, GEM SLNs, and EGCG SLNs with an IC_{50} value of approximately 10 $\mu\text{g/mL}$ for GEM-EGCG SLNs. The wound healing (scratch) assay revealed that GEM-EGCG SLNs could significantly avert the migration of A549 cells, with 85 % of uncovered scratch wound area after 48 hours of incubation at 5 $\mu\text{g/mL}$ which increased to around 90 % at 50 $\mu\text{g/mL}$. Cellular uptake studies revealed that SLNs were able to be internalized into the nuclei of cells which could be due to their small particle size in the nanometer range. The high apoptotic rate shown by GEM-EGCG SLNs depicts its better anti-tumor activity against A549 cells as compared to other treatment groups along with ROS production which mediated the apoptosis of A549 cells. We found that GEM-EGCG SLNs were stable for the observation period of 3 months with only slight changes in the values of particle size, PDI, zeta potential, and percent entrapment efficiency. Overall, the histopathological studies of the lungs of tumor bearing mice and safety assessment of GEM-EGCG SLNs postulates the synergistic anti-tumor potential of epigallocatechin-3-gallate co-loaded with gemcitabine in biocompatible solid lipid nanoparticles for use as an anti-cancer therapeutic agent against lung cancer.

LIST OF FIGURES

Figure No.	Description	Page No.
1	Pie chart depicting the percent of deaths related to different types of cancers as per data documented by GLOBOCAN 2020 and the International Agency for Research on Cancer.	4
2	Categorization of lung cancer.	4
3	Common risk factors associated with lung cancer.	8
4	Diagrammatic representation of delivery of gemcitabine and epigallocatechin-3-gallate loaded solid lipid nanoparticles (GEM-EGCG SLNs) in the mice model of lung cancer and its mechanism of action.	13
5	Putative mechanism of GEM-EGCG SLNs as anticancer agent.	14
6	Schematic diagrammatic representation of the preparation of solid lipid nanoparticles by double emulsification solvent evaporation method.	63
7	Calibration curves of (A) GEM in PBS (pH 5.5) at wavelength 268 nm; (B) EGCG in PBS (pH 5.5) at wavelength 280 nm; (C) GEM in plasma at wavelength 268 nm; and (D) EGCG in plasma at wavelength 280 nm.	83
8	Selectivity of (A) GEM in PBS (pH 5.5) at wavelength 268 nm; (B) EGCG in PBS (pH 5.5) at wavelength 280 nm; (C) GEM in plasma at wavelength 268 nm; and (D) EGCG in plasma at wavelength 280 nm.	87
9	Predicted vs. actual graph for all the four responses viz., particle size, PDI, entrapment efficiency of GEM, and entrapment efficiency of EGCG.	90
10	3-D Contour plots for the responses viz., particle size, PDI, entrapment efficiency of GEM, and entrapment efficiency of EGCG.	91
11	Diagrammatic representation of gemcitabine and epigallocatechin-3-gallate loaded solid lipid nanoparticles (GEM-EGCG SLNs).	96
12	(A) Average particle size distribution of SLNs; (B) Scanning electron microscopy images of GEM-EGCG SLNs, which depicts the surface properties of the formulation indicating spherical shape of GEM-EGCG	99

	SLNs.	
13	ATR graphs of pure GEM, pure EGCG, physical mixture of GEM and EGCG, GEM-EGCG SLNs, GMS, PF-127, PVA, and HSPC.	101
14	TGA graphs of GEM-EGCG SLNs, pure GEM, pure EGCG, and GMS, TGA graphs depict weight loss as a function of temperature.	103
15	DSC graphs of GEM-EGCG SLNs, pure GEM, pure EGCG, and GMS.	104
16	Cumulative percentage drug release profile of GEM-EGCG SLNs, GEM SLNs, and EGCG SLNs for the release of GEM and EGCG at pH 5.5 for a time period of 48 hours.	106
17	Release kinetics graphs of GEM from GEM-EGCG SLNs for release kinetic models viz., Zero order, First order, Higuchi, Hixson Crowell, and Korsmeyer Peppas at pH 5.5.	107
18	Release kinetics graphs of EGCG from GEM-EGCG SLNs for release kinetic models viz., Zero order, First order, Higuchi, Hixson Crowell, and Korsmeyer Peppas at pH 5.5.	108
19	The % cell viability versus concentration graph for different formulations against A549 cell lines.	109
20	(A) Wound healing (scratch) assay depicting inhibitory potential of different treatments on A549 cell lines, (B) shows a bar graph of percent scratch wound area uncovered by cells after incubation for 24 hours and 48 hours at concentrations of 5 µg/mL (B(i)) and 50 µg/mL (B(ii)) of different treatments groups.	111
21	Fluorescence microscopy images of A549 cells depicting cellular uptake of rhodamine-tagged GEM-EGCG SLNs (Rh-GEM-EGCG SLNs) and rhodamine-tagged SLNs (Rh-SLNs) at 4 and 12 hours.	113
22	Apoptotic graphs depicting the percent apoptotic cell death by different formulations	115
23	ROS graphs of different formulations depicting percentage of ROS generation.	116
24	Pharmacokinetic profile of GEM and EGCG in plasma and lungs for GEM-EGCG SLNs, GEM SLNs, EGCG SLNs, pure GEM, and pure EGCG.	121
25	Pharmacokinetic profile of GEM and EGCG in lungs and plasma of mice	122

	after intravenous bolus administration of GEM-EGCG SLNs.	
26	Graphical representation of the comparison of AUC ₀₋₈ for different formulations in plasma and lungs upon intranasal administration (Statistical values represent *** (p < 0.001), and ** (p < 0.01)).	122
27	(A) IVIS images of mice after intranasal instillation of GEM-EGCG SLNs at different time points, depicting qualitative biodistribution of GEM-EGCG SLNs in the body; (B) IVIS images depicting biodistribution of GEM-EGCG SLNs in the vital organs after 48 hours; (C) Graph representing ROI (region of interest) quantification in terms of bioluminescence signals of GEM-EGCG SLNs by IVIS imaging system in the lungs of mice at different time points.	127
28	Bar diagram representation of relative biodistribution of GEM and EGCG in the vital organs after 1 hour and 6 hours of intranasal instillation of GEM-EGCG SLNs, EGCG SLNs, GEM SLNs, GEM, and EGCG (statistical values represents *** (p < 0.001), ** (p < 0.01), and ns (non-significant)).	129
29	Histological images from the groups- (A) diseased control group; (B) GEM-EGCG SLNs treatment group; (C) GEM SLNs treatment group; (D) EGCG SLNs treatment group(E) GEM drug control group; and (F) EGCG drug control group.	131
30	(1) Images of lungs excised from different treatment groups at the end of study (3 months); (2) Survival analysis curve- Kaplan Meier curve, depicting the survival of different treatment groups over 100 days; (3) Curve depicting body weight changes in subjects from different treatment groups over the treatment period (abbreviations: GEM- gemcitabine; EGCG- epigallocatechin-3-gallate; GEM-EGCG SLNs- gemcitabine and epigallocatechin-3-gallate loaded solid lipid nanoparticles; GEM SLNs- gemcitabine loaded solid lipid nanoparticles; EGCG SLNs- epigallocatechin-3-gallate loaded solid lipid nanoparticles; blank SLNs- blank solid lipid nanoparticles; B[a]P- benzo[a]pyrene; +B[a]P- receiving benzo[a]pyrene; +B[a]P/+GEM-EGCG SLNs- receiving benzo[a]pyrene and GEM-EGCG SLNs; +B[a]P/+GEM SLNs- receiving benzo[a]pyrene and GEM-SLNs; +B[a]P/+EGCG SLNs- receiving benzo[a]pyrene and EGCG	132

	SLNs)	
31	Histopathological images of the major metabolizing organs viz., kidney and liver to assess the safety of SLNs.	134
32	Bar graph representation of the hemolysis rate (%) at different concentrations of GEM-EGCG SLNs, GEM, EGCG, and positive control (triton X-100). The supporting photograph is from the experiment of the hemolysis study performed in different groups (NC: negative control; PC: positive control).	135
33	Histopathological images of the nose of mice after intranasal instillation of GEM-EGCG SLNs (treatment group) compared with control group.	136

ACKNOWLEDGEMENT

*I would like to express my heartfelt gratitude to the **Almighty** who empowered me to work with all my energy and calibre. I revere the patronage and moral support extended with love, by my family whose passionate encouragement made it possible for me to complete my Ph.D. project.*

*It gives me immense pleasure to be a part of the **Indian Institute of Technology (Banaras Hindu University), Varanasi, Uttar Pradesh, India.***

*It is my radiant sentiment to place on record my best regards, and most profound sense of gratitude to my supervisor **Dr. Ruchi Chawla**, Associate Professor, Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (Banaras Hindu University) for her precious and careful guidance and support round the clock for completing my research work. It has been an honor to be her Ph.D. student. Throughout my tenure, she provided encouragement, advice, good teaching, and lots of good ideas along with moral values of life to make my research more impactful. She is the one who always pushes a student to be the best version of themselves and helps them to flourish well in their career and overall growth. I appreciate all her contributions of time, ideas, and suggestions to make my Ph.D. experience productive and stimulating.*

*I would like to express my special appreciation and gratitude to the Research Progress Evaluation Committee (RPEC) members: **Dr. Ruchi Chawla, Prof. B. Mishra, and Dr. Abha Mishra**, for their extensive personal and professional guidance for productive research. My joy knows no bounds in expressing my cordial gratitude to **Prof. B. Mishra** for his guidance and teachings that helped me in impactful scientific research.*

The support extended by Dr. Pradip Paik School of Biomedical Engineering, Indian Institute of Technology (Banaras Hindu University), Varanasi, Uttar Pradesh, and Dr. Avanish Singh

Parmar, Department of Physics, Indian Institute of Technology (Banaras Hindu University), Varanasi, Uttar Pradesh, and their students is also acknowledged for their generous support.

Also, my sincere thanks to all my teachers, Prof. Siva Hemalatha, Prof. Sushant Kumar Srivastava, Prof. Sushil Kumar Singh, Dr. Alakh Niranjana Sahu. Dr. Gyan Prakash Modi, Dr. M. S. Muthu, Dr. Sunil Kumar Mishra, Dr. Senthil Raja A, Dr. Vinod Tiwari, Dr. Ashish Kumar Agrawal. Dr. Prasanta Kumar Nayak, Dr. Shreyans Kumar Jain, Dr. Dinesh Kumar, Dr. Rajnish, Dr. Deepak Kumar, Dr. Jairam Meena, and Dr. Arun Khatri of Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (Banaras Hindu University) for their support, helpful lessons, encouragement, and discussions.

*My sincere thanks to **Prof. Amit Patra (Director), Prof. Devendra Singh (Dean of Academic Affairs), Prof. Rajesh Kumar (Dean of Student's Affairs) and Prof. Dr. Sairam Krishnamurthy(Head of the Department, Department of Pharmaceutical Engineering and Technology)**, for providing healthy work atmosphere with the best facilities and intellectually inspiring environment. I am thankful to Central Instrument Facility, IIT BHU and Sophisticated Instrument Facility of Department of Pharmaceutical Engineering and Technology, for providing advanced research equipment facility for conducting my research work. I am also thankful to finance section of Indian Institute of Technology (Banaras Hindu University) for providing my fellowship and research support grant. I also give my sincere thanks to Dr. Vinod Tiwari, who provided his expert guidance for conducting in-vivo experimentation and taking due care of Animal ethical guidelines. My thanks also go to all the staff members of the Department of Pharmaceutical Engineering and Technology, for providing me with instrumental facilities. I am extremely thankful to Mr. Akhila Nand Upadhyay, Mr. Virendra Kumar, Smt. Archana Singh, Mr. Arun Kumar, and Mr. Mohd. Jameel for their invaluable technical inputs and non-technical staff Mr. Atul Kumar*

Gupta, Mr. Yashwant Singh, Mr. Anand Kumar, and Mr. Surya Pratap Singh for their friendly behaviour and ever-ready help during my research project.

I also express my deep appreciation to my seniors Dr. Rinki Verma, Dr. Varsha Rani, Dr. Krishan Kumar, Dr. Kirti Wasnik, Dr. Vishnupriya, Dr. Kancharla Bhanukiran, and Dr. Sangeeta Hazarika for their invaluable support.

I humbly extend my thanks to all my lab mates and friends Dr. Anagha Gadepalli, Dr. Debadatta Mohapatra, Dr. Dulla Naveen Kumar, Mr. Saurabh Kumar Srivastava, Ms. Bhagwati Bhardwaj, Ms. Poorvi Saraf, Ms. Divya Pareek, and Sunil who co-operated me in this regard.

I convey my great sense of thankfulness to all the animals whom I used during various studies and my condolences to the animals that were sacrificed for the completion of the research work.

Date:

Place: IIT BHU, Varanasi

(Mohini Mishra)




Department of Pharmaceutical Engineering & Technology
Indian Institute of Technology
(Banaras Hindu University)
Varanasi-221005

DECLARATION BY THE CANDIDATE

I, **Mohini Mishra**, certify that the work embodied in the thesis is my own bona fide work and carried out by me under the supervision of **Dr. Ruchi Chawla, Associate Professor** from **July 2019 to March 2025**, at the **Department of Pharmaceutical Engineering and Technology**, Indian Institute of Technology (Banaras Hindu University), Varanasi. The matter embodied in this thesis has not been submitted for the award of any other degree/diploma.

I declare that I have faithfully acknowledged and given credits to the research workers wherever their works have been cited in my work in the thesis. I further declare that I have not willfully copied any other's work, paragraphs, text, data, results, etc., reported in journals, books, magazines, report dissertations, thesis, etc., or available at websites and have not included them in this Ph.D. thesis and have not cited as my own work.


Date: 15/9/2025



(Mohini Mishra)

Place: IIT (BHU)

CERTIFICATE BY THE SUPERVISOR

It is certified that the above statement made by the student is correct to the best of my/our knowledge.


(Dr. Ruchi Chawla)
Associate Professor
Department of Pharmaceutical Engineering & Technology
INDIAN INSTITUTE OF TECHNOLOGY
(BANARAS HINDU UNIVERSITY)
VARANASI-221005


(Prof. Sairam Krishnamurthy)

Head of the Department
विभागाध्यक्ष / Head
भैषजकीय अभियांत्रिकी एवं प्रौद्योगिकी विभाग /
Department of Pharmaceutical Engineering & Technology
भारतीय प्रौद्योगिकी संस्थान / INDIAN INSTITUTE OF TECHNOLOGY
(बनारस हिन्दू विश्वविद्यालय) / (BANARAS HINDU UNIVERSITY)
वाराणसी-२२१००५ / Varanasi-221005



CERTIFICATE

It is certified that the work contained in the thesis titled "**DEVELOPMENT & EVALUATION OF INTRA-NASAL LIPID NANOCARRIERS FOR LUNG CANCER**" by **Mohini Mishra** has been carried out under my supervision and this work has not been submitted elsewhere for a degree.

It is further certified that the student has fulfilled all the requirements of Course work, Comprehensive, Candidacy, SOTA, and Pre-submission seminar.


Dr. Ruchi Chawla
Associate Professor

Department of Pharmaceutical Engineering and Technology
Indian Institute of Technology (Banaras Hindu University),
Varanasi-221005, Uttar Pradesh



Department of Pharmaceutical Engineering & Technology
Indian Institute of Technology
(Banaras Hindu University)
Varanasi-221005

COPYRIGHT TRANSFER CERTIFICATE


Title of the Thesis: "DEVELOPMENT & EVALUATION OF INTRA-NASAL LIPID NANOCARRIERS FOR LUNG CANCER"

Name of the Student: Ms. Mohini Mishra

Copyright Transfer

The undersigned hereby assigns to the Indian Institute of Technology (Banaras Hindu University), Varanasi all rights under copyright that may exist in and for the above thesis submitted for the award of the "*Doctor of Philosophy*".

Date: 15/9/2025


(Mohini Mishra)

Place: IIT (BHU)

Note: However, the author may reproduce or authorize others to reproduce material extracted verbatim from the thesis or derivative of the thesis for the author's personal use provided that the source and the Institute's copyright notice are indicated.

LIST OF TABLES

Table No.	Description	Page No.
1	Enlisting the coded and actual values for all three factors studied during optimization	61
2	Design matrix predicted by Design Expert® 13 Trial version (M/S Stat-Ease, Minneapolis USA) for 2-level 3-factor factorial design.	61
3	Enlisting various drug release models and their equations.	66
4	Depicting various parameters of the median-effect curve for the calculation of CI.	70
5	HPLC validation parameters for determination of GEM and EGCG in PBS (pH 5.5) and plasma	84
6	Accuracy & precision (Intra-day and inter-day precision) studies of the developed analytical HPLC method for GEM and EGCG in PBS (pH 5.5) and plasma	85
7	Independent factors considered during the optimization of the formulation along with the responses studied.	88
8	Statistical analysis (ANOVA) table for all the selected responses of the factorial model.	89
9	FIT statistics table for all the studied responses.	89
10	The solutions predicted by the model upon validation.	92
11	Correlation coefficient (R^2) values for different models at pH 5.5 for GEM and EGCG from GEM-EGCG SLNs.	106
12	Stability data of GEM-EGCG SLNs for 3 months for the characteristic particle size, PDI, zeta potential, and percent entrapment efficiency	118
13	Pharmacokinetic parameters for GEM and EGCG in plasma upon intranasal administration	119
14	Pharmacokinetic parameters for GEM and EGCG in lungs upon intranasal administration	120

List of abbreviations

GEM- Gemcitabine

EGCG- Epigallocatechin-3-gallate

SLNs- Solid lipid nanoparticles

GEM-EGCG SLNs- Gemcitabine epigallocatechin-3-gallate loaded solid lipid nanoparticles

DCM- Dichloromethane

HPLC- High-performance liquid chromatography

UV- Ultraviolet

MRT- Mean residence time

AUC- Area under curve

QbD- Quality by design

PVA- Poly vinyl alcohol

PF-127- Pluronic F-127

HSPC- Hydrogenated soy phosphatidylcholine

GMS- Glyceryl monostearate

B(a)P- Benzopyrene

FBS- Fetal bovine serum

MTT- 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

DMEM- Dulbecco's Modified Eagle Medium

DMSO- Dimethyl sulfoxide

OVAT- One variable at a time

rpm- Rotations per minute

W/O- Water in oil

W/O/W- Water in oil in water

PDI- Poly dispersity index

ATR- Attenuated total reflectance

DSC- Differential scanning calorimetry

TGA- Thermogravimetric analysis

pH- Potential of hydrogen

PBS- Phosphate buffer saline

CO₂- Carbon dioxide

Kg- Kilogram
mg- Milligram
mL- Milliliter
 μ L- Microliter
nm- Nanometer
 μ M- Micromolar
h- Hours
 $^{\circ}$ C- Degree Celsius
min- Minutes
i.n.- Intranasal
i.v.- Intravenous
DAPI- 4',6-diamidino-2-phenylindole
Rh- Rhodamine
DCFDA- 2',7'-dichlorofluorescein diacetate
ROS- Reactive oxygen species
EDTA- Ethylenediamine tetra acetate
 H_2O_2 - Hydrogen peroxide
DTI- Drug targeting index
IVIS- *In vivo* imaging system
p- Probability coefficient
 R^2 - Correlation coefficient
NC- Negative control
PC- Positive control
Dt-Absorbance of the test sample
Dnc- Absorbance of the negative control
Dpc- Absorbance of the positive control

Dedicated to My Son
Ashwattha